News

The Manila Times31m
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
Announce initial clinical data from Cohort 1 in the Phase 1/2 trial of PM359 for p47 phox CGD in 2025. The initial readout ...
CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)
CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to ...
The Manila Times31m
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights
Updated clinical data in heavily pre-treated, CAR-T naïve patients with B-NHL shows prolonged duration of response, with ...